BRPI0416945A - biomarcadores para a eficácia do tratamento com hormÈnio paratiróide e calcitonina - Google Patents

biomarcadores para a eficácia do tratamento com hormÈnio paratiróide e calcitonina

Info

Publication number
BRPI0416945A
BRPI0416945A BRPI0416945-0A BRPI0416945A BRPI0416945A BR PI0416945 A BRPI0416945 A BR PI0416945A BR PI0416945 A BRPI0416945 A BR PI0416945A BR PI0416945 A BRPI0416945 A BR PI0416945A
Authority
BR
Brazil
Prior art keywords
biomarkers
efficacy
treatment
hormone
parathyroid hormone
Prior art date
Application number
BRPI0416945-0A
Other languages
English (en)
Inventor
Maria Bobadilla
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416945A publication Critical patent/BRPI0416945A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

"BIOMARCADORES PARA A EFICáCIA DO TRATAMENTO COM HORMÈNIO PARATIRóIDE E CALCITONINA". A presente invenção refere-se a análise do perfil genético de múltiplos órgãos dos resultados de uma administração, a um indivíduo, de calcitonina do salmão ou um análogo de hormónio paratiróide que proporciona biomarcadores da eficácia do tratamento com calcitonina e da eficácia do tratamento com hormónio paratiróide ou análogo de hormónio paratiróide. Entre os biomarcadores estão os perfis de expressão dos genes para proteína de ligação Y-box, BMP~ S~, FGF~ S~, IGF~ S~, VEGF, glicoproteína <244>-2-HS (AHSG), OSF, receptores nucleares (família esteróide/tiroidiano) e outros. Os resultados obtidos corroboram o efeito anabólico da calcitonina do salmão sobre o metabolismo ósseo.
BRPI0416945-0A 2003-11-25 2004-11-24 biomarcadores para a eficácia do tratamento com hormÈnio paratiróide e calcitonina BRPI0416945A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52502503P 2003-11-25 2003-11-25
PCT/EP2004/013347 WO2005053731A1 (en) 2003-11-25 2004-11-24 Biomarkers for the efficacy of calcitonin and parathyroid hormone treatment

Publications (1)

Publication Number Publication Date
BRPI0416945A true BRPI0416945A (pt) 2007-02-13

Family

ID=34652293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416945-0A BRPI0416945A (pt) 2003-11-25 2004-11-24 biomarcadores para a eficácia do tratamento com hormÈnio paratiróide e calcitonina

Country Status (12)

Country Link
US (1) US20070099828A1 (pt)
EP (1) EP1689427A1 (pt)
JP (1) JP2007522100A (pt)
KR (1) KR20060110304A (pt)
CN (1) CN1905894A (pt)
AU (1) AU2004294268A1 (pt)
BR (1) BRPI0416945A (pt)
CA (1) CA2546111A1 (pt)
IL (1) IL175575A0 (pt)
MX (1) MXPA06005950A (pt)
RU (1) RU2006122632A (pt)
WO (1) WO2005053731A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5528461B2 (ja) * 2008-10-17 2014-06-25 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるビグリカンの使用
EP2496948B1 (en) * 2009-11-05 2018-01-10 University of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
WO2012125914A1 (en) * 2011-03-16 2012-09-20 University Of Delaware Injectable delivery system for heparan sulfate binding growth factors
CN112748241A (zh) * 2019-10-16 2021-05-04 浙江中医药大学附属第二医院 一种用于检测i型骨质疏松症的蛋白芯片及其制作方法与应用
CN112574991B (zh) * 2020-12-17 2023-03-17 安徽师范大学 一种寡核苷酸、载体及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175437A (ja) * 1983-03-25 1984-10-04 Teikoku Hormone Mfg Co Ltd 高コレステロ−ル血症改善剤
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5514365A (en) * 1988-10-11 1996-05-07 Schiapparelli Salute S.P.A. Pharmaceutical compositions comprising calcitonin for intranasal administration
JPH02229119A (ja) * 1989-02-28 1990-09-11 Toyo Jozo Co Ltd 動脈硬化予防および治療剤
AU2001292905A1 (en) * 2000-09-19 2002-04-02 Curagen Corporation Method of identifying osteoregenerative agents using differential gene expression
CN1526025A (zh) * 2001-05-16 2004-09-01 ��˹��ŵ�� 作为预后和治疗靶标的乳腺癌中表达的基因
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
EP1470246A2 (en) * 2001-10-31 2004-10-27 Novartis AG Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene

Also Published As

Publication number Publication date
US20070099828A1 (en) 2007-05-03
WO2005053731A1 (en) 2005-06-16
IL175575A0 (en) 2006-09-05
RU2006122632A (ru) 2008-02-10
CA2546111A1 (en) 2005-06-16
AU2004294268A1 (en) 2005-06-16
JP2007522100A (ja) 2007-08-09
CN1905894A (zh) 2007-01-31
KR20060110304A (ko) 2006-10-24
EP1689427A1 (en) 2006-08-16
MXPA06005950A (es) 2006-07-06

Similar Documents

Publication Publication Date Title
Varela et al. One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption
Kanzleiter et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy
Gautam et al. Micro-architectural changes in cancellous bone differ in female and male C57BL/6 mice with high-fat diet-induced low bone mineral density
Trost et al. Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease
Lin et al. The VGF-derived peptide TLQP62 produces antidepressant-like effects in mice via the BDNF/TrkB/CREB signaling pathway
Holecki et al. Relationship between body fat mass and bone metabolism
Liu et al. HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis
Gil et al. Genotype-specific regulation of oral innate immunity by T2R38 taste receptor
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0518616A (pt) métodos para tratar doenças relacionadas com retinol, degeneração ou distrofia macular e diabetes tipo i ou tipo ii
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
Ding et al. Resveratrol promotes nerve regeneration via activation of p300 acetyltransferase-mediated VEGF signaling in a rat model of sciatic nerve crush injury
BRPI0511126A (pt) métodos de tratamento utilizando proteìnas de ligação de albumina como alvos
Álvarez et al. Human β-defensin 1 update: Potential clinical applications of the restless warrior
BRPI0508865B8 (pt) dispositivo de liberação de medicamento visível por raio x
BR0314619A (pt) Análogos de ghrh
Alikhani et al. Therapeutic effect of localized vibration on alveolar bone of osteoporotic rats
Krutko et al. Natural aging as as a sequential poly-systemic syndrome
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
Schwarz et al. Status of drug development for the prevention and treatment of osteoporosis
BRPI0416945A (pt) biomarcadores para a eficácia do tratamento com hormÈnio paratiróide e calcitonina
Muta et al. Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes
Yagi et al. Effects of lactoferrin on the differentiation of pluripotent mesenchymal cells
Sato et al. A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia
Moradi et al. Concurrent exercise training and Murf-l and Atrogin-1 gene expression in the vastus lateralis muscle of male Wistar rats

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.